Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Bluebird bio Inc (NASDAQ: BLUE) closed at $0.90 in the last session, down -0.39% from day before closing price of $0.90. In other words, the price has decreased by -$0.39 from its previous closing price. On the day, 7.09 million shares were traded. BLUE stock price reached its highest trading level at $0.9447 during the session, while it also had its lowest trading level at $0.8903.
Ratios:
We take a closer look at BLUE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.
Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 173429248 and an Enterprise Value of 227794720. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.98 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at 10.485 whereas that against EBITDA is -1.729.
Stock Price History:
The Beta on a monthly basis for BLUE is 0.82, which has changed by -0.79310346 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -27.40%, while the 200-Day Moving Average is calculated to be -62.49%.
Shares Statistics:
According to the various share statistics, BLUE traded on average about 8.29M shares per day over the past 3-months and 6944440 shares per day over the past 10 days. A total of 192.74M shares are outstanding, with a floating share count of 189.83M. Insiders hold about 1.51% of the company’s shares, while institutions hold 61.87% stake in the company. Shares short for BLUE as of 1713139200 were 32620441 with a Short Ratio of 3.93, compared to 1710460800 on 34040621. Therefore, it implies a Short% of Shares Outstanding of 32620441 and a Short% of Float of 18.07.
Earnings Estimates
The current rating of Bluebird bio Inc (BLUE) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.On average, analysts expect EPS of -$0.64 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.29 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.27 and -$2.26 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.61, with 13.0 analysts recommending between -$0.95 and -$2.86.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $10.16M. It ranges from a high estimate of $17.3M to a low estimate of $7.7M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62kFor the next quarter, 11 analysts are estimating revenue of $19.55M. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $12.76M.
A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $29M, resulting in an average revenue estimate of $35.3M. In the same quarter a year ago, actual revenue was $3.6MBased on 14 analysts’ estimates, the company’s revenue will be $122.03M in the next fiscal year. The high estimate is $167.5M and the low estimate is $78M.
